Find Locations
For hours, walk-ins and appointments.Synonyms
- Norpace®
Expected Turnaround Time
2 - 3 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Specimen Requirements
Specimen
Serum or plasma
Volume
1 mL
Minimum Volume
0.3 mL
Container
Red-top tube, lavender-top (EDTA) tube, or green-top (heparin) tube. Do not use a gel-barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage time, the decrease in drug level due to absorption may be clinically significant.
Collection
Transfer separated serum or plasma to a plastic transport tube.
Storage Instructions
Room temperature
Stability Requirements
Temperature | Period |
|---|---|
Room temperature | 14 days |
Refrigerated | 14 days |
Frozen | 14 days |
Freeze/thaw cycles | Stable x3 |
Causes for Rejection
Gel-barrier tube; hemolysis; lipemia; icteric specimen
Test Details
Use
Evaluate toxicity; monitor therapeutic levels
Methodology
Immunoassay (IA)
Reference Interval
Therapeutic: 2.0−5.0 μg/mL
Critical Value
Potentially toxic: >5.0 μg/mL
Additional Information
Disopyramide shares electrophysiologic properties with quinidine and procainamide. Up to 80% of oral dose is absorbed. Half-life is 4 to 10 hours. Eighty percent of the drug is excreted in the urine. Dosage must be modified (dosage intervals prolonged) in patients with renal failure. Serious toxic effects are depression of myocardial contractility and disturbances in myocardial conduction. Other effects include dry mouth, constipation, urinary hesitancy, and blurred vision. Metabolite N-desisopropyl disopyramide is also pharmacologically active. Concomitant treatment with phenytoin may lead to decreased serum levels of disopyramide. There may be cumulative effect with other Class I antiarrhythmic drugs (lidocaine, procainamide).
References
American Medical Association, Division of Drugs and Toxicology. Drug Evaluations Subscription. Chicago, Ill: AMA; Winter 1993.
Jürgens G, Graudal NA, Kampmann JP. Therapeutic monitoring of antiarrhythmic drugs. Clin Pharmacokinet. 2003; 42(7):647-663. 12844326
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 007864 | Disopyramide, Serum | 3576-6 | 007865 | Disopyramide, Serum | ug/mL | 3576-6 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf